Crescita Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Crescita Therapeutics has a total shareholder equity of CA$16.1M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$22.7M and CA$6.6M respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$8.44m |
| Equity | CA$16.06m |
| Total liabilities | CA$6.62m |
| Total assets | CA$22.68m |
Recent financial health updates
Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)
Oct 25
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope
May 30Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge
Jan 04Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?
Nov 18Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)
May 05Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 10
Financial Position Analysis
Short Term Liabilities: CTX's short term assets (CA$16.3M) exceed its short term liabilities (CA$6.0M).
Long Term Liabilities: CTX's short term assets (CA$16.3M) exceed its long term liabilities (CA$585.0K).
Debt to Equity History and Analysis
Debt Level: CTX is debt free.
Reducing Debt: CTX has no debt compared to 5 years ago when its debt to equity ratio was 20.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 08:17 |
| End of Day Share Price | 2025/02/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Crescita Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.